FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3022118302> ?p ?o ?g. }

• W3022118302 endingPage "1185" @default.
• W3022118302 startingPage "1178" @default.
• W3022118302 abstract "Background In men with castration-sensitive prostate cancer (CSPC), the HSD3B1 c.1245A>C variant has been reported to be associated with shorter responses to first-line androgen-deprivation therapy (ADT). Here, we evaluated the association between the inherited HSD3B1 c.1245A>C variant and outcomes from metastatic castration-resistant prostate cancer (mCRPC) after first-line treatment with abiraterone (Abi) or enzalutamide (Enza). Patients and methods Patients with mCRPC (n = 266) were enrolled from two centers at the time of starting first-line Abi/Enza. Outcomes after Abi/Enza included best prostate-specific antigen (PSA) response, treatment duration, and overall survival (OS). Outcomes after first-line ADT were determined retrospectively, and included treatment duration and OS. As was prespecified, we compared patients with the homozygous variant HSD3B1 genotype (CC genotype) versus the combined group with the heterozygous (AC) and homozygous wild-type (AA) genotypes. Results Among the 266 patients, 22 (8.3%) were homozygous for the HSD3B1 variant (CC). The CC genotype had no association with PSA response rate; the median Abi/Enza treatment duration was 7.1 months for the CC group and 10.3 months for the AA/AC group (log rank P = 0.34). Patients with the CC genotype had significantly worse OS, with median survival at 23.6 months for the CC group and 30.7 months for the AA/AC group (log rank P = 0.02). In multivariable analysis adjusting for age, Gleason score, PSA, prior chemotherapy, and M1 disease, the association between the CC genotype and OS remained significant (hazard ratio 1.78, 95% confidence interval 1.03–3.07, P = 0.04). Poor outcome after first-line ADT in the CC group was also observed when evaluating retrospective ADT duration data for the same combined cohort. Conclusions In this large two-center study evaluating the HSD3B1 c.1245 genotype and outcomes after first-line Abi/Enza, homozygous variant (CC) HSD3B1 genotype was associated with worse outcomes. Novel therapeutic strategies are needed to enable treatment selection based on this genetic marker." @default.
• W3022118302 created "2020-05-13" @default.
• W3022118302 creator A5000824765 @default.
• W3022118302 creator A5018107876 @default.
• W3022118302 creator A5018623684 @default.
• W3022118302 creator A5031522630 @default.
• W3022118302 creator A5033829154 @default.
• W3022118302 creator A5045477350 @default.
• W3022118302 creator A5046900095 @default.
• W3022118302 creator A5057048206 @default.
• W3022118302 creator A5068348417 @default.
• W3022118302 creator A5069346188 @default.
• W3022118302 creator A5072378199 @default.
• W3022118302 creator A5075880342 @default.
• W3022118302 creator A5077552075 @default.
• W3022118302 creator A5085732690 @default.
• W3022118302 date "2020-09-01" @default.
• W3022118302 modified "2023-10-12" @default.
• W3022118302 title "Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype" @default.
• W3022118302 cites W1584828549 @default.
• W3022118302 cites W2100965400 @default.
• W3022118302 cites W2110534364 @default.
• W3022118302 cites W2137467802 @default.
• W3022118302 cites W2148643283 @default.
• W3022118302 cites W2150865892 @default.
• W3022118302 cites W2157592394 @default.
• W3022118302 cites W2166918329 @default.
• W3022118302 cites W2252849995 @default.
• W3022118302 cites W2404460725 @default.
• W3022118302 cites W2511096688 @default.
• W3022118302 cites W2514486754 @default.
• W3022118302 cites W2560832549 @default.
• W3022118302 cites W2587831721 @default.
• W3022118302 cites W2588655921 @default.
• W3022118302 cites W2604800509 @default.
• W3022118302 cites W2620798309 @default.
• W3022118302 cites W2721799027 @default.
• W3022118302 cites W2765198289 @default.
• W3022118302 cites W2765319709 @default.
• W3022118302 cites W2786529129 @default.
• W3022118302 cites W2788160989 @default.
• W3022118302 cites W2794972561 @default.
• W3022118302 cites W2809857833 @default.
• W3022118302 cites W2888253244 @default.
• W3022118302 cites W2911465702 @default.
• W3022118302 cites W2915440535 @default.
• W3022118302 doi "https://doi.org/10.1016/j.annonc.2020.04.473" @default.
• W3022118302 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32387417" @default.
• W3022118302 hasPublicationYear "2020" @default.
• W3022118302 type Work @default.
• W3022118302 sameAs 3022118302 @default.
• W3022118302 citedByCount "18" @default.
• W3022118302 countsByYear W30221183022020 @default.
• W3022118302 countsByYear W30221183022021 @default.
• W3022118302 countsByYear W30221183022022 @default.
• W3022118302 countsByYear W30221183022023 @default.
• W3022118302 crossrefType "journal-article" @default.
• W3022118302 hasAuthorship W3022118302A5000824765 @default.
• W3022118302 hasAuthorship W3022118302A5018107876 @default.
• W3022118302 hasAuthorship W3022118302A5018623684 @default.
• W3022118302 hasAuthorship W3022118302A5031522630 @default.
• W3022118302 hasAuthorship W3022118302A5033829154 @default.
• W3022118302 hasAuthorship W3022118302A5045477350 @default.
• W3022118302 hasAuthorship W3022118302A5046900095 @default.
• W3022118302 hasAuthorship W3022118302A5057048206 @default.
• W3022118302 hasAuthorship W3022118302A5068348417 @default.
• W3022118302 hasAuthorship W3022118302A5069346188 @default.
• W3022118302 hasAuthorship W3022118302A5072378199 @default.
• W3022118302 hasAuthorship W3022118302A5075880342 @default.
• W3022118302 hasAuthorship W3022118302A5077552075 @default.
• W3022118302 hasAuthorship W3022118302A5085732690 @default.
• W3022118302 hasBestOaLocation W30221183021 @default.
• W3022118302 hasConcept C104317684 @default.
• W3022118302 hasConcept C109825262 @default.
• W3022118302 hasConcept C121608353 @default.
• W3022118302 hasConcept C126322002 @default.
• W3022118302 hasConcept C135763542 @default.
• W3022118302 hasConcept C143998085 @default.
• W3022118302 hasConcept C2776421732 @default.
• W3022118302 hasConcept C2776551883 @default.
• W3022118302 hasConcept C2780192828 @default.
• W3022118302 hasConcept C54355233 @default.
• W3022118302 hasConcept C61367390 @default.
• W3022118302 hasConcept C71924100 @default.
• W3022118302 hasConcept C86803240 @default.
• W3022118302 hasConceptScore W3022118302C104317684 @default.
• W3022118302 hasConceptScore W3022118302C109825262 @default.
• W3022118302 hasConceptScore W3022118302C121608353 @default.
• W3022118302 hasConceptScore W3022118302C126322002 @default.
• W3022118302 hasConceptScore W3022118302C135763542 @default.
• W3022118302 hasConceptScore W3022118302C143998085 @default.
• W3022118302 hasConceptScore W3022118302C2776421732 @default.
• W3022118302 hasConceptScore W3022118302C2776551883 @default.
• W3022118302 hasConceptScore W3022118302C2780192828 @default.
• W3022118302 hasConceptScore W3022118302C54355233 @default.
• W3022118302 hasConceptScore W3022118302C61367390 @default.
• W3022118302 hasConceptScore W3022118302C71924100 @default.
• W3022118302 hasConceptScore W3022118302C86803240 @default.

• next